Recent data indicates increasing hesitancy towards both COVID-19 and influenza vaccination. We studied attitudes towards COVID-19 booster, influenza, and combination influenza-COVID-19 booster vaccines in a nationally representative sample of US adults between May and June 2021 (n = 12,887). We used pre-qualification quotes to ensure adequate sample sizes for minority populations. Overall vaccine acceptance was 45% for a COVID-19 booster alone, 58% for an influenza vaccine alone, and 50% for a combination vaccine. Logistic regression showed lower acceptance among female, Black/African American, Native American/American Indian, and rural respondents. Higher acceptance was found among those with college and post-graduate degrees. Despite these differences, our results suggest that a combination vaccine may provide a convenient method of dual vaccination that may increase COVID-19 vaccination coverage.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650809 | PMC |
| http://dx.doi.org/10.1016/j.vaccine.2021.11.097 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A chimeric mRNA vaccine of S-RBD with HA conferring broad protection against influenza and COVID-19 variants.
PLoS Pathog
September 2024
CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, People's Republic of China.
Article Synopsis
- Influenza and COVID-19 are two major respiratory diseases that have led to significant health challenges worldwide, prompting the need for an effective combined vaccine to avoid multiple doses.
- Researchers created a chimeric protein subunit vaccine combining parts of the influenza virus and the SARS-CoV-2 virus, demonstrating effectiveness in mouse models against various strains.
- An mRNA vaccine candidate was developed from this chimeric antigen, showing strong immune responses and complete protection in mice against both influenza and different strains of SARS-CoV-2, with the potential for easy adaptation to new variants.
Estimating the full health and economic benefits of current and future influenza vaccines.
BMC Med
July 2023
Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, 30307, USA.
In the dynamic landscape of respiratory virus vaccines, it is crucial to assess the value of novel mRNA and combination influenza/COVID-19 vaccines in low- and middle-income countries. Modeling studies, such as the one conducted by Waterlow et al., provide vital information about the cost-benefit potential of these products compared to currently licensed vaccines.
View Article and Find Full Text PDFUptake rates and attitudes to influenza and COVID-19 vaccination in pregnancy - a prospective cohort study.
Ir J Med Sci
February 2024
Department of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Dublin, Ireland.
Article Synopsis
- * There was a notable increase in influenza vaccination compared to a similar study in 2016, suggesting improved awareness or access.
- * Factors impacting vaccination rates included age, obesity, co-morbidities, ethnicity, and type of antenatal care, leading to the recommendation that clinics emphasize the importance of vaccination and consider offering both vaccines on the same day.
Exploring Factors Associated with Chinese-Americans' Willingness to Receive an Additional Hypothetical Annual Dose of the COVID-19 Vaccine.
Vaccines (Basel)
January 2023
Department of Health Sciences, Towson University, Towson, MD 21252, USA.
Chinese-Americans are one of the largest groups of Asian-Americans in the US with distinctive behavioral and cultural characteristics that influence health service use. Although Chinese-Americans have significantly higher COVID-19-related mortality rates, relative to other racial and ethnic groups, limited literature is available examining their willingness to accept the COVID-19 vaccine. With recent development of the combination influenza-COVID-19 vaccine by biotechnology companies to mitigate COVID-19 infection, we examined factors associated with Chinese-Americans' acceptance of hypothetical annual doses of COVID-19 vaccination before the vaccine rollout.
View Article and Find Full Text PDFThis study aims to obtain higher-level evidence by overviewing the Meta-analysis of Lianhua Qingwen preparations in the treatment of viral diseases including influenza, coronavirus disease 2019(COVID-19), and hand, foot and mouth disease(HFMD). CNKI, Wanfang, VIP, China Clinical Trial Registry(ChiCTR), PubMed, EMbase, Web of Science, and Cochrane Library were searched for the Meta-analysis about the treatment of viral diseases with Lianhua Qingwen preparations from the database establishment to April 1, 2022. After literature screening and data extraction, AMSTAR2 and the grading of recommendations assessment, development and evaluations(GRADE) system were used to assess the methodological quality and evidence quality, respectively, and then the efficacy and safety outcomes of Lianhua Qingwen preparations in the treatment of viral diseases were summarized.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!